Insights Into Acute Lymphoblastic Leukemia (ALL) 2025

Perspectives of community physicians on the treatment of ALL

National #1 – January 28, 2025

Faculty Chair

Jae Park, MD

Memorial Sloan Kettering Cancer Center, New York, NY, USA

National #2 – January 28, 2025

Faculty Chair

Daniel DeAngelo, MD

Dana-Farber Cancer Institute, Boston, MA, USA

National #3 – March 18, 2025

Faculty Chair

Matthew Wieduwilt, MD

Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA

Central – April 5, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Califorina/Nevada – April 14, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Florida – April 16, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Texas – April 23, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Northeast – April 29, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

National #4 – April 30, 2025

Faculty Chair

Lori Muffly, MD

Stanford University, Stanford, CA, USA

Southwest – May 2, 2025

Faculty Chair

Caspian Oliai, MD

UCLA Health, Los Angeles, CA, USA

National #5 – May 20, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

National #6 – May 22, 2025

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

National #7 – May 28, 2025

Faculty Chair

Gregory Roloff, MD

UChicago Medicine, Chicago, IL, USA

National #8 – July 30, 2025

Faculty Chair

Ibrahim Aldoss, MD

City of Hope, Duarte, CA, USA

Florida – August 9, 2025

Faculty Chair

Rawan Faramand, MD

Moffitt Cancer Center, Tampa, FL, USA

More Information

  • Virtual series

More Information

  • Virtual series

More Information

  • Virtual series

More Information

  • Dallas, TX
  • Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas

More Information

  • Virtual series
  • California, Nevada

More Information

  • Virtual series
  • Florida

More Information

  • Virtual series
  • Texas

More Information

  • Virtual series
  • Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Virtual series

More Information

  • Phoenix, AZ
  • Arizona, Colorado, Nevada, New Mexico, Southern California, Utah

More Information

  • Virtual series

More Information

  • Virtual series

More Information

  • Virtual series

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of ALL
  • Disease state and data presentations were developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies were obtained: blinatumomab, ponatinib, inotuzumab ozogamicin, liposomal vincristine, and chimeric antigen receptor (CAR) T-cell therapy

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.